Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease

Abstract

Background: Osteoporosis is highly prevalent in CKD patients and is characterized by low bone mass leading to decreased bone strength. It is associated with an increased risk of fracture, thus increasing morbidity and mortality. Bisphosphonate administration decreases fracture risk in postmenopausal females with osteoporosis. There are limited studies showing effects of short term alendronate administration on BMD in predialysis osteoporotic patients with CKD.

Methods: This study was conducted on fifty adult patients with chronic kidney disease. Patients were divided into two groups. Group A consisted of seventeen patients with CKD stage 3 (eGFR 45-30 ml/min/1.73m2) and Group B comprised thirty three patients with CKD stage 4 (eGFR 30-15 ml/min/1.73m2). The study included male patients between age 18-75 years and premenopausal non pregnant females older than 18 years of age. All the patients were osteoporotic having T score < −2.5 on DEXA scan. The patients were administered 70 mg alendronate tablet once a week for 6 weeks. Renal parameters, parathyroid hormone, calcium, phosphorous and alkaline phosphatase levels were assayed at baseline for 6 months. Serum (iPTH) level (pg/ml) was measured by chemiluminescent immune assay (CLIA) method and serum 25 Hydroxy Vitamin D level (ng/ml) was measured by enzyme linked immunosorbent assay (ELISA) method. Bone Mineral Density (BMD) was measured at baseline for 6 months, by dual energy x-ray absorptiometry at lumbar spine and neck of femur and lowest values were included. The results were obtained for T score, Z score and bone mineral density (g/cm2).

Results: The BMD, T score and Z score increased in both groups after 6 months with a statistically significant difference in the treatment group. In Group A, T score, Z score and BMD (g/cm2) increased from −2.60±0.086, −2.13±0.28, and 0.80±0.008 at baseline to −2.57±0.097, −2.11±0.26 and 0.81±0.008 after six months. In Group B, the T score, Z score and BMD (g/cm2) increased from −3.17±0.24, −2.82±0.33 and 0.738±0.03 to −3.16±0.25, −2.66±0.95 and 0.743±0.03 after six months with a statistically significant difference. eGFR decreased in both groups but the difference was statistically non-significant (P>0.05). The serum iPTH levels increased after 6 months in both groups with a statistically insignificant difference. There was an increase in serum calcium and decrease in serum phosphate levels after six months, however the difference was statistically insignificant (p>0.05). The SAP values decreased in both groups after six months with a statistically insignificant difference. The main side-effect in the alendronate group was the occurrence of gastroesophageal reflux symptoms in two subjects.

Conclusion: Low-dose alendronate, administered for a limited duration, appears to be well tolerated in CKD patients. The BMD increased in both groups suggesting a bone-preserving effect of alendronate.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Eknoyan G, Lameire N, Barsoum R. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-4.

  • 2. Block GA, Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. In: Olgard K (ed). Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD. National Kidney Foundation: New York, 2006, 77-92.

  • 3. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006; 69: 1945-53.

  • 4. Ersoy FF, Passadakis SP, Tam P, Mammos ED, Katopodis PK, Ozener C et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006; 24(1): 79-86.

  • 5. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2) : 75-85.

  • 6. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996; 97: 2692-6.

  • 7. Liberman UA, Weiss SR, Broll J. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.

  • 8. Lomashvili KA, MonierFaugere MC, Wang X, Malluche HH, O’Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75(6): 617-25.

  • 9. Trabulus S, Altiparmak MR, Apaydin S. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol and alendronate combined with alfacalcidol. Transplant Proc 2008; 40: 160-6.

  • 10. Negri AL. Vascular calcifications in chronic kidney disease: are there new treatments? Current Vascular Pharmacology. 2005; 3(2): 181-4.

  • 11. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 2007; 16: 329-35.

  • 12. Klawansky S, Komaroff E, Cavanaugh PFJ, Mitchell DY, Gordon MJ, Connelly JE et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int 2003; 14: 570-6.

  • 13. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L et al. Population based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004; 19(12): 1945-54.

  • 14. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76: 1399-406.

  • 15. Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrol 2005; 10(4): 393-9.

  • 16. Shahbazian H, Tamadon MR, Mowla SK, Shayanpour S, Hayati F, Shojaii M et al. Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial. J Parathyroid Dis 2016; 4(1): 3-6.

  • 17. Shahbazian H, Mowla K, Shahbazian HB, Peydayesh B, Ehsanpour A. Efficacy and safety of alendronate in the prevention of bone loss in renal transplant recipients. Indian J Nephrol 2007; 17: 61-5

  • 18. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A et al.. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22(4): 503-8.

  • 19. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89(9): 4246-53.

  • 20. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 56(1): 57-68.

  • 21. Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Lahteenmaki T et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol. 1998; 83: 125-31.

OPEN ACCESS

Journal + Issues

Search